Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(20):1443-1444; doi:10.1093/jnci/djj447
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Mack, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mack, G. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Epigenetic Cancer Therapy Makes Headway

George S. Mack

The first 10% of the full text of this article appears below.

The new science of epigenetics is leading investigators to innovative methods of treating cancers. And they are doing it using decades-old chemotherapy drugs more successfully and with less toxicity than in the past.

These drugs, including those that target two well-known epigenetic pathways, are already on the market, and new ones are being investigated. Now oncologists are looking at ways to use those drugs in combination or in different doses to make them more effective. They might even be able to overcome failures in solid tumors.

"Epigenetic therapy works. It produces remissions, and it is helping patients live longer, healthier lives with less toxicity," says Jean-Pierre Issa of University of Texas M. D. Anderson Cancer Center in Houston. "It is a concept that has taken 15 years to develop—the idea of treating cancer not by killing the cells but by . . . [Full Text of this Article]

Understanding Epigenetics

A Different Dose

Turning Disappointment Around


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CA Cancer J ClinHome page
W. W. Ma and A. A. Adjei
Novel Agents on the Horizon for Cancer Therapy
CA Cancer J Clin, March 1, 2009; 59(2): 111 - 137.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Esteller
Epigenetics in Cancer
N. Engl. J. Med., March 13, 2008; 358(11): 1148 - 1159.
[Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y. Kanai and S. Hirohashi
Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state
Carcinogenesis, December 1, 2007; 28(12): 2434 - 2442.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
L. Fini, M. Selgrad, V. Fogliano, G. Graziani, M. Romano, E. Hotchkiss, Y. A. Daoud, E. B. De Vol, C. R. Boland, and L. Ricciardiello
Annurca Apple Polyphenols Have Potent Demethylating Activity and Can Reactivate Silenced Tumor Suppressor Genes in Colorectal Cancer Cells
J. Nutr., December 1, 2007; 137(12): 2622 - 2628.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Esteller
Epigenetic gene silencing in cancer: the DNA hypermethylome
Hum. Mol. Genet., April 15, 2007; 16(R1): R50 - R59.
[Abstract] [Full Text] [PDF]